Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00124527
Status:
COMPLETED
Last Update Posted:
2021-06-16
First Post:
2005-07-26
Brief Title:
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally AdvancedMetastatic Differentiated Thyroid Cancer
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors The purpose of this study is to assess the efficacy and safety of irofulvencapecitabine combination therapy in patients with anaplastic medullary or locally advancedmetastatic differentiated thyroid cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None